$2.36
5.42% yesterday
Nasdaq, Nov 15, 10:08 pm CET
ISIN
US7743741024
Symbol
RMTI

Rockwell Medical, Inc. Stock price

$2.36
-1.09 31.54% 1M
+0.65 37.72% 6M
+0.47 24.60% YTD
+0.15 6.56% 1Y
-3.24 57.90% 3Y
-20.64 89.76% 5Y
-114.03 97.98% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.14 5.42%
ISIN
US7743741024
Symbol
RMTI
Sector

Key metrics

Market capitalization $76.11m
Enterprise Value $72.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 27.28
EV/Sales (TTM) EV/Sales 0.73
P/S ratio (TTM) P/S ratio 0.77
P/B ratio (TTM) P/B ratio 2.61
Revenue growth (TTM) Revenue growth 22.37%
Revenue (TTM) Revenue $98.92m
EBIT (operating result TTM) EBIT $580.00k
Free Cash Flow (TTM) Free Cash Flow $2.64m
Cash position $18.27m
EPS (TTM) EPS $-0.06
P/E forward negative
P/S forward 0.77
EV/Sales forward 0.73
Short interest 2.67%
Show more

Is Rockwell Medical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Rockwell Medical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Rockwell Medical, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Rockwell Medical, Inc. forecast:

Buy
100%

Financial data from Rockwell Medical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
99 99
22% 22%
100%
- Direct Costs 82 82
13% 13%
83%
17 17
105% 105%
17%
- Selling and Administrative Expenses 14 14
9% 9%
14%
- Research and Development Expense 0.19 0.19
83% 83%
0%
2.77 2.77
150% 150%
3%
- Depreciation and Amortization 2.19 2.19
14% 14%
2%
EBIT (Operating Income) EBIT 0.58 0.58
107% 107%
1%
Net Profit -1.53 -1.53
84% 84%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Rockwell Medical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rockwell Medical, Inc. Stock News

Positive
Seeking Alpha
3 days ago
Despite a 39% stock drop yesterday, Rockwell Medical's strong Q3 results and upcoming catalyst provide a solid buying opportunity for risk-takers. The stock's dip was due to reduced orders from its largest customer, but Rockwell is diversifying its customer base and entering the at-home dialysis market. Strategic initiatives, including new supply contracts and product line growth, are expected ...
Neutral
Seeking Alpha
3 days ago
Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell...
Neutral
Business Wire
4 days ago
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced financial and operational results for the three and nine months ended September 30, 2024.
More Rockwell Medical, Inc. News

Company Profile

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Hackensack, NJ.

Head office United States
CEO Mark Strobeck
Employees 237
Founded 1995
Website www.rockwellmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today